Clinical trial
Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
NCT00226369 · Boston Children's Hospital, Other · Completed
Key facts
| NCT number | NCT00226369 |
|---|---|
| Title | Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery |
| Official title | Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy/Safety of CY-1503 (Cylexin) in Prevention of Reperfusion Injury in Neonates/Infants Undergoing Hypothermic Cardiopulmonary Bypass |
| Lead sponsor | Boston Children's Hospital, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Congenital Heart Defects |
| Intervention type | Drug |
| Interventions | CY-1503 |
| Enrollment | 242 |
| Start date | Dec 1, 1997 |
| Completion | Jun 1, 2001 |
| First posted | Sep 27, 2005 |
| Last update posted | Feb 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: